Abstract:Highlights • PI3K/AKT/mTOR pathway targeting agents are important in the second line treatment of ER-positive metastatic breast cancer. • Medications targeting this pathway have an emerging role in the treatment of high-risk patients in the first line. • Managing toxicities of these agents has been a challenge and toxicity plays an important role in medication selection. • New treatments targeting this pathway are being developed and have the promise of efficacy with improved tolerability. Mutations in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway occur in 30%-40% of patients with advanced hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) breast cancer. For most patients, endocrine therapy with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor is the first-line treatment. Recent studies indicate that adding inavolisib, a PI3Kα inhibitor, to palbociclib/fulvestrant benefits patients with endocrine-resistant HR+/HER2− metastatic breast cancer with a PIK3CA mutation. Alpelisib and capivasertib are both US Food and Drug Administration (FDA) approved in combination with fulvestrant in patients with endocrine-resistant HR+/HER2−, PIK3CA -mutant metastatic breast cancer, both with activity in the post-CDK4/6 setting. Capivasertib added to fulvestrant is the first AKT inhibitor to show a significant progression-free survival benefit with a trend for overall survival benefit and the only approved option for patients with phosphate and tensin homolog (PTEN) or AKT alterations. Toxicity profiles of all agents necessitate careful patient selection. Several mutant-selective and pan-mutant-selective novel inhibitors are under investigation with the potential to improve tolerability and efficacy.

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer

Targeting the PI3K pathway in cancer: are we making headway?

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer

RAS/MAPK Activation is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Synergistic Effects of Multi-Level Targeting of the MAPK and PI3-kinase Pathways in Breast Cancer Cells.

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer

Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment

Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer

PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects